Vilip 1 (Visinin Like Protein 1) Neuronal Biomarker is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
VILIP-1 (Visinin-Like Protein 1), also known as VSNL1, is a neuronal calcium sensor protein that serves as a biomarker for neuronal injury in Alzheimer's disease and other neurodegenerative disorders[1].
VILIP-1 belongs to the neuronal calcium sensor (NCS) family of proteins, which are expressed primarily in neurons and involved in calcium-dependent signaling pathways. In the brain, VILIP-1 is found in hippocampal pyramidal neurons, cortical neurons, and cerebellar granule cells[2]. CSF and plasma VILIP-1 levels reflect the degree of neuronal damage and have emerged as a promising biomarker for neurodegenerative diseases.
| Property | Value |
|---|---|
| Gene | VSNL1 (Visinin-Like 1) |
| Protein Name | Visinin-like protein 1 (VILIP-1) |
| UniProt ID | P62760 |
| Molecular Weight | ~22 kDa |
| Brain Expression | Hippocampus, Cortex, Cerebellum |
| Cellular Localization | Cytosolic, membrane-associated |
VILIP-1 participates in several neuronal processes[3]:
Elevated VILIP-1 in cerebrospinal fluid and blood indicates neuronal injury[4][5]:
| Condition | CSF VILIP-1 Level | Clinical Interpretation |
|---|---|---|
| Alzheimer's Disease | ↑ Significantly elevated | Primary neuronal injury marker |
| MCI due to AD | ↑ Moderately elevated | Early neuronal damage |
| Vascular Dementia | ↑ Elevated | Ischemic neuronal injury |
| Parkinson's Disease | Normal to slightly elevated | Less cortical involvement |
| Frontotemporal Dementia | Variable | Depends on subtype |
| Healthy Controls | Low baseline | Normal neuronal integrity |
VILIP-1 is released into extracellular fluids through[6]:
VILIP-1 is often combined with other biomarkers[7]:
| Biomarker | Primary Target | Sample Type |
|---|---|---|
| VILIP-1 | Neuronal injury | CSF, Plasma |
| p-tau | Tau pathology | CSF |
| Aβ42 | Amyloid pathology | CSF |
| NfL | Axonal injury | CSF, Plasma |
| Neurogranin | Synaptic dysfunction | CSF |
VILIP-1 is used as a biomarker in AD therapeutic trials[8]:
Changes in VILIP-1 levels may indicate:
| Method | Sample | Advantages |
|---|---|---|
| ELISA | CSF, Plasma | High throughput, validated |
| Simoa | Plasma | Ultra-sensitive for low concentrations |
| Western Blot | CSF | Confirmation of specific isoforms |
| Mass Spectrometry | CSF, Plasma | High specificity, multiplex capable |
Ongoing research is exploring the utility of VILIP-1 in blood-based biomarker panels for widespread clinical screening. Advances in ultrasensitive assay technologies have enabled reliable detection of VILIP-1 in plasma, expanding the feasibility of population-wide screening programs. Studies are investigating VILIP-1's potential for detecting prodromal Alzheimer's disease in asymptomatic individuals.
Recent studies have explored VILIP-1 in combination with other neuronal and glial biomarkers for enhanced diagnostic accuracy. The development of blood-based VILIP-1 assays has expanded clinical utility beyond CSF testing. Ongoing research focuses on establishing age-adjusted reference ranges and disease-specific cutoff values for clinical implementation.
Proper sample handling is critical for accurate VILIP-1 measurement. CSF samples should be collected using standardized protocols to avoid contamination with blood products. Centrifugation within 2 hours of collection and storage at -80°C are recommended to maintain biomarker stability. Plasma samples require similar careful handling with EDTA or heparin collection tubes.
Clinical implementation requires thorough analytical validation including assessment of intra-assay and inter-assay precision, dilution linearity, and sample stability. Reference laboratories have established quality control procedures to ensure consistent results across testing platforms.
The development of ultrasensitive immunoassays has enabled reliable detection of VILIP-1 in plasma and serum, significantly expanding clinical applicability. Several studies have demonstrated good correlation between CSF and blood VILIP-1 levels, supporting the use of blood-based testing for large-scale screening programs.
VILIP-1 shows promise for personalized medicine applications in Alzheimer's disease, potentially guiding treatment decisions and monitoring therapeutic response. Integration with other biomarkers may enable more precise disease staging and prognosis.
Recent studies have explored VILIP-1 in combination with other neuronal and glial biomarkers for enhanced diagnostic accuracy. The development of blood-based VILIP-1 assays has expanded clinical utility beyond CSF testing. Ongoing research focuses on establishing age-adjusted reference ranges and disease-specific cutoff values for clinical implementation.
The study of Vilip 1 (Visinin Like Protein 1) Neuronal Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Laterza OF, Modur VR, Crimmins DL, et al. Identification of novel brain biomarkers. Clin Chem. 2006;52(9):1713-1721. DOI:10.1373/clinchem.2006.070169 ↩︎
Bernstein HG, Baumann B, Danos P, et al. Regional and cellular distribution of visinin-like protein 1 (VILIP-1) in human brain. Brain Res. 1999;820(1-2):123-130. DOI:10.1016/S0006-8993(9801339-9 ↩︎
Burgoyne RD. Neuronal calcium sensor proteins: Generating diversity in neuronal Ca2+ signalling. Trends Neurosci. 2007;30(2):75-84. DOI:10.1016/j.tins.2006.12.004 ↩︎
Tarawneh R, D'Angelo G, Macy E, et al. Visinin-like protein-1: Diagnostic utility and prognostic value in Alzheimer's disease. Alzheimers Dement. 2012;8(4):283-291. DOI:10.1016/j.jalz.2011.10.004 ↩︎
Lee JM, Blennow K, Andreasen N, et al. The brain injury biomarker VILIP-1 is increased in the cerebrospinal fluid of patients with Alzheimer's disease. Neuroimage. 2008;39(1):308-311. DOI:10.1016/j.neuroimage.2007.07.052 ↩︎
Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-216. DOI:10.1016/S1474-4422(1270291-0 ↩︎
Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: A systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673-684. DOI:10.1016/S1474-4422(1600070-3 ↩︎
Blennow K, Zetterberg H. The past and future of Alzheimer's disease fluid biomarkers. J Alzheimers Dis. 2018;62(3):1125-1140. DOI:10.3233/JAD-170773 ↩︎